Chronic kidney disease (CKD) is a common clinical condition with significant adverse consequences for the patient. It is recognized as a significant public health problem throughout the world (1). Many publications report the prevalence of CKD in the general population, however there are considerable variation in methods for sampling general population and assessment of kidney function across studies (2). This makes comparison of studies rather difficult, however worldwide prevalence of adult CKD is about 10%, reaching up to 50% in high-risk population (3). Late recognition and diagnosis of disease inevitably leads to kidney failure (1). In this case the only possible therapeutic measure is dialysis or transplantation in health care systems where such treatment is available. In those countries, where access to dialysis and transplantation service may be limited or unavailable, the final consequence of progressive CKD is death. Earlier stages of kidney disease are often asymptomatic and are usually discovered through various comorbid conditions, and may be reversible. It is of great importance, due to right time treatment and improving the quality of life of patients with CKD, but also because of the significant financial savings, to identify disease at an early stage where it is still possible to stop or slow down progression (1). Although, to this point, there had not been official complete epidemiological studies conducted regarding CKD (prof. Mirjana Sabljar Matovinović, personal communication), the availability of treatment in Croatia includes both, dialysis and transplantation (4).
In 2002 the US Kidney Disease Outcomes Quality Initiative (KDOQI) group published the Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Update of these guidelines and recommendations: Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease was released in 2012 under the direction of Kidney Disease: Improving Global Outcomes (KDIGO). Our national recommendations for laboratory diagnosis of chronic kidney disease are mainly based on the 2012 KDIGO guidelines, and written permission was obtained to reproduce the parts of the KDIGO guidelines. KDIGO guidelines are the product of cooperation of a large number of international experts who created recommendations, among other things, to be used for good laboratory practice in the diagnosis and management of CKD.
Chronic kidney disease is defined as an abnormality of kidney structure or function with implications on the health of an individual, and it is present for more than three months. Chronic kidney disease is a general term for heterogeneous disorders affecting kidney structure and function with variable clinical presentation (1). Rational approach to the diagnosis and evaluation of CKD involves simultaneous assessment and monitoring of renal function (through estimated glomerular filtration rate (eGFR), serum creatinine) and kidney damage (albuminuria and/or proteinuria) (Table 1).
One of the prominent criteria for the diagnosis of CKD is decreased GFR value (< 60 mL/min/1.73m2). GFR is widely accepted as the best index of kidney function. The normal value in young adult men and woman is approximately 125 mL/min/1.73m2. Values below 15 mL/min/1.73m2 indicate kidney failure and the person can be identified as a candidate for dialysis or renal replacement therapy/kidney transplantation (1). The role of laboratory medicine in diagnosis and management of CKD is of great importance because a very simple test can identify people who are at risk of developing CKD. All that is required is measuring the concentration of serum creatinine and reporting of eGFR, using the available predictive equations.
For an initial assessment of proteinuria the following measurements are recommended (in descending order of preference):
In all cases an early morning urine sample is preferred, but does not exclude spot urine samples. Measuring the concentration of urine albumin is preferred to measuring the concentration of urine total protein. Use of urine albumin measurement as the preferred test for proteinuria detection will improve the sensitivity, quality, and consistency of the approach to early detection and management of kidney disease. Albumin (or total protein) concentration in the urine sample should be reported in proportion to the concentration of creatinine (ACR or PCR) in the same sample to minimize the influence of the patient’s hydration and the concentration of the urine sample. The reporting of the results is the same for both first morning and spot urine samples, respectively. A positive finding of albuminuria in a random sample of urine needs to be confirmed in the next morning void urine. If a more accurate assessment of albuminuria (or total proteinuria) is required, it is recommended to measure albumin excretion rate (AER) or total protein excretion rate in a timed urine sample (1, 5, 6). The choice of a suitable timed sample type should be of a laboratory manager. Adequate sample type, time of collection and instructions for patients should be provided by institution.
Some of the other laboratory criteria for diagnosing CKD include urine sediment abnormalities as markers of kidney damage (Table 1). This may include some formed elements, such as renal tubular cells, red blood cells (RBC) casts, white blood cell (WBC) casts, coarse granular casts, wide casts and large numbers of dysmorphic RBCs. Abnormalities of electrolytes (Table 1) may result from disorders of renal tubular reabsorption and secretion. These syndromes are uncommon but pathognomonic of kidney disease (1).
Grading of CKD is based almost exclusively on two laboratory parameters: eGFR (GFR categories 1 to 5 (G1 – G5)) and albuminuria (albuminuria categories 1 to 3 (A1 – A3)) (Table 2). It is also used for the prognosis of progression of the disease (1).
Depending on the category, patients are classified as low-risk patients, highlighted in green, moderate risk (yellow), high risk (orange) and very high risk patients (highlighted in red).
CKD testing using eGFR and ACR should be offered to people with any of the following risk factors:
acute kidney injury
cardiovascular disease (ischaemic heart disease, chronic heart failure, peripheral vascular disease or cerebral vascular disease)
structural renal tract disease, recurrent renal calculi or prostatic hypertrophy
multisystem diseases with potential kidney involvement – for example, systemic lupus erythematosus
family history of end-stage kidney disease (GFR category G5) or hereditary kidney disease
opportunistic detection of haematuria (7).
Recently, it was shown that laboratory diagnostics of chronic kidney disease in Croatia is not standardized (8). There is a large heterogeneity among Croatian medical biochemistry laboratories regarding creatinine methods and used reference intervals and types of preferred samples for urine albumin (or protein). The most important issue that occured is the fact that laboratories still use non-standardized methods for creatinine results and do not report eGFR values. Also, the majority of laboratories do not measure urine albumin, especially in primary care health setting (8). These facts set the background for the process of standardization and harmonization in this area of laboratory medicine. These national guidelines, based on the relevant 2012 KDIGO Guideline (1), represent the first step in accomplishing this goal.
Key factors for laboratories implementing the national guidelines for the diagnosis and management of CKD are:
Ensure good communication between laboratory professionals and relevant clinicians, such as nephrologists or specialists in general/family medicine,
Ensure all patients are provided with the same availability of laboratory diagnostics,
Ensure creatinine assays are traceable to isotope dilution mass spectrometry (IDMS) method and have minimal bias and acceptable imprecision,
Select the appropriate GFR estimating formula. Recommended equation is the 2009 Chronic Kidney Disease Epidemiology Collaboration (CKD – EPI) equation,
In reporting the key laboratory tests (creatinine, eGFR, urine albumin-to-creatinine ratio (ACR), urine protein-to-creatinine ratio (PCR)) use the appropriate reporting units,
Provide adequate information on limitations to creatinine measurement (9).
The national recommendations are mainly based on the KDIGO 2012 guidelines, however, novel literature findings are also incorporated. Our main goal was to provide recommendations that can be easily applied in every medical biochemistry laboratory in Croatia. The draft of the recommendations was sent to numerous national and international experts for their comments. The manuscript was also made available for public consultation. All comments were carefully considered and incorporated into the final version of the recommendations.
The document consists of four main parts with corresponding subheadings:
The manuscript is organized to identify critical points in four major laboratory tests used in basic laboratory diagnostics of CKD. It is rather difficult to give unique and uniform recommendations, regarding a large heterogeneity amongst methods and populations. Our intention was to point out to some weak points in pre- and analytical phase, but every laboratory must set their own specifications for method performance and handling the specimens, according to their possibilities and conditions.
An easy-to-follow step-by-step approach in implementation of the recommendations is shown in Appendix 1.
To ensure the better flow of information in implementing national guidelines laboratories can use the provided template (Appendix 2) (10).
An important limiting factor in the use of predictive equations for GFR estimation is an accurate method for determining serum creatinine concentration.
There are numerous well known preanalytical variations that affect serum creatinine concentration which are listed in the Table 3.
The majority of listed variations are non-controllable, however both laboratory professionals and clinicians should be aware of those limitations. The laboratory professionals are referred to previously mentioned Appendix 2 which will be of assistance in communication with patients, as well as with the ordering physicians. For a minor part of variations that can be controlled regarding sample quality, laboratory professionals are referred to the published national recommendations for venous and capillary blood sampling (11, 12).
Creatinine, in a non-separated serum sample, which is in contact with a blood clot, is stable for 24 hours. In a separate serum sample creatinine is stable for 7 days at room temperature (20-25 °C), or stored in a refrigerator (2-8 °C). Serum samples stored at - 20 °C are stable for 3 months with 10 freeze-thaw cycles (13).
To universally implement eGFR based on serum creatinine measurements, standardization of routine serum creatinine measurements is required. For the measurement of serum creatinine, laboratories should use the recommended method with calibration traceable to international standard reference material and minimal bias compared to the IDMS method (1).
Desirable and optimal specification for imprecision, bias and total error according to biological variation database (14, 15) are shown in Table 4.
Recommended methods for serum creatinine measurements in Croatia are: photometric compensated Jaffé method traceable to IDMS method and enzymatic method traceable to IDMS method and The National Institute of Standards and Technology Standard Reference Material (NIST SRM) 967 for creatinine in serum (16). However, there is emerging evidence that enzymatic creatinine assays lead to less variability in measurements of serum creatinine and are preferably used in clinical practice in order to generate more reliable GFR estimates (17-19).
Standardization (compensation) of photometric Jaffé method involves changing the values of calibrators in terms of traceability to the IDMS method and change of corresponding intercept (or factor B, depending on the analyzer). Considering the fact that there are many creatinine assays available that may not be IDMS traceable, and that for assays which may be IDMS traceable, the information supplied does not make this clear to the user (20), for new values of calibrators, controls and intercept, laboratory professionals should contact the person in charge of applications from companies providing reagents, controls and calibrators or whose analyzer is on which creatinine is measured. The list of available creatinine assays, as well as traceability information, is given in the Appendix 3. However, laboratory professionals should be aware that this list is susceptible to changes and they should always be correctly informed by the latest Information for use (IFU) leaflet.
Standardization of calibration does not correct for analytical interferences. The enzymatic assays may be less influenced by non-creatinine chromogens compared to the Jaffé assays (21, 22), but no procedure was unaffected. The most common analytical interferences are caused by endogenous substances: high bilirubin concentration, glucose, proteins, pyruvate, β-hydroxybutyric acid, low albumin, as well as many drugs (cephalosporins, dobutamine, lidocaine) (23). High bilirubin concentrations may interfere with the Jaffé method, where the assay absorbance is near the bilirubin absorbance peak of ~456 nm. Jaffé reaction may also be affected by lipemia and/or haemolysis. Haemolysed samples that contain fetal haemoglobin (HbF) interfere with the Jaffé reaction, and it is possible to obtain negative creatinine results (24). Management of lipemic samples was extensively explained in the review by Nikolac et al. (25).
The influence of interfering substances is greater at creatinine concentrations within reference range than at higher concentrations. Magnitude and direction of bias in creatinine concentration depends on the details of implementation of the method principle (26). The influence of interfering substances is less frequent with the enzymatic procedures, however no procedure is unaffected and is method and analyzer dependent (21, 27). Interference (endogenous or exogenous) if unrecognized lead to false laboratory result and consequently to incorrect diagnosis. To systematize corrective actions, as a part of the total quality system, when interference appears first step must be manufacturer´s method specification in which are listed interference studies conducted by the manufacturer (28). However, it was shown that there are serious discrepancies between manufacturer’s declarations and measured data (29). Each laboratory should verify the data declared by the manufacturer and define its own acceptability criteria (30).
Because urine contains relatively little or no protein, both enzymatic and Jaffé method are suitable for urine creatinine measurement (1).
When reporting serum and urine creatinine concentrations obtained by a standardized assay, laboratories should use revised reference intervals published by Croatian chamber of medical biochemists (CCMB) in 2010 (31, 32) which are shown in Table 5.
|Analyte||SI Units||Reference intervals|
|Serum creatinine||μmol/L||Prenatal (umbilical cord)||46 – 86|
|newborn babies||0 – 14 days||27 – 81|
|male, female||2 months ≤ 1 year||14 – 34|
|male, female||1 y ≤ 3 y||15 – 31|
|male, female||3 y ≤ 5 y||23 – 37|
|male, female||5 y ≤ 7 y||25 – 42|
|male, female||7 y ≤ 9 y||30 – 48|
|male, female||9 y ≤ 11 y||28 – 57|
|male, female||11 y ≤ 13 y||37 – 63|
|male, female||13 y ≤ 15 y||40 – 72|
|male||adults (18 – 74 y)||64 – 104|
|female||adults (18 – 74 y)||49 – 90|
(24 hour urine sample)
|mmol/24 hour||male, female||3 – 8 y||1.0 – 6.0|
|male, female||9 – 12 y||1.5 – 12.5|
|male, female||13 – 17 y||2.6. – 16.5|
|male||adults||7.7 – 21.3|
|female||adults||5.9 – 14.1|
(first morning sample)
|mmol/L||male||adults||3.5 – 22.9|
|female||adults||2.5 – 19.2|
|y – years. (Reproduced and adapted with the permission of Croatian Chamber of Medical biochemists, document in Croatian. Available at: http://www.hkmb.hr/obavijesti/arhiva2010/arhiva_2010.html.)|
The applicability of the recommended “common” reference intervals in all Croatian laboratories measuring serum creatinine concentrations were confirmed in the study conducted by Flegar-Meštrić et al. (33). This fulfils the prerequisite for implementation of international guidelines for early diagnosis and prediction of progression of chronic kidney disease using glomerular filtration rate CKD-EPI estimating equation (34, 35).
Children show lower reference ranges for total protein, thus the protein error in Jaffé method is considerably smaller, which, in consequence, with restandardized Jaffé-type assays, could lead to negative values in children with a decreased muscle mass (36). Therefore, the only recommended method for the measurement of serum creatinine in pediatric patients (individuals younger than 18 years) is enzymatic assay (37).
The persisting problem of pediatric reference intervals has been substantially reduced with the establishment of a new comprehensive database of pediatric reference intervals as a part of the Canadian Laboratory Initiative in Pediatric Reference Intervals (CALIPER) study (38, 39). It should assist laboratorians and pediatricians in interpreting test results more accurately. There are already some transference studies with other analytical platforms and local populations, as recommended by the CLSI (40, 41). Laboratory professionals should also be aware of the International Federation for Clinical Chemistry and Laboratory Medicine (IFCC) Pediatric Reference Range Initiatives with many useful information on this delicate topic (42).
Methods for serum creatinine measurement should be traceable to IDMS method and NIST SRM 967.
For urine creatinine measurement both enzymatic and Jaffé method are suitable.
When reporting serum and urine creatinine values obtained by a standardized assay, laboratories should use revised reference intervals published by CCMB.
The recommended method for serum creatinine measurement in pediatric patients (< 18 years) is the enzymatic assay.
For pediatric reference intervals consult CALIPER database (http://www.sickkids.ca/Caliperproject/intervals/index.html) and other available literature data, such as IFCC Pediatric Reference Range Initiatives (http://www.ifcc.org/task-force-paediatric-laboratory-medicine-web-pages/paediatric-reference-range-initiatives/).
The recommended equation for GFR estimation in adult population (≥ 18 years) is CKD-EPI equation (1, 43, 44). The equation includes four variables: serum creatinine concentration, age, sex and race (Table 6) (34). Although all equations for GFR estimation are essentially mathematical abstractions that relate patients to the populations from which the equations were derived (45), there is growing body of evidence that CKD-EPI equation is superior in general population (5, 46), as well as in diabetic patients (47-49).
In situations where GFR estimating equations are limited including extremes of body size and age, conditions after limb amputation, pregnancy, severe malnutrition or obesity, muscle wasting diseases, paraplegia and quadriplegia, vegetarian diet, rapidly changing kidney function, when determining eligibility for kidney donation or adjusting dosage of toxic drugs that are excreted by the kidneys and in research projects in which estimating glomerular filtration rate is a primary goal, GFR should be measured using standardized creatinine clearance measurement (1, 50).
eGFR may be falsely decreased after a meal of high meat content, as blood creatinine concentration increases after meal intake (51).
Blood creatinine is predominantly derived from muscle, e.g. a muscular young man may have increased serum creatinine concentration and a falsely lowered eGFR. eGFR increases by 2.3 mL/min/kg of lean mass in healthy men (52).
Low eGFR finding should be confirmed with a repeated sample taken after avoidance of meat for at least 12 hours. Spurious causes of low eGFR, such as high muscle mass, should be considered. Additionally, a low eGFR should prompt a check for proteinuria assessment (51).
Diagnosis, prognosis prediction and progression of CKD using eGFR is not based on comparing the values to population based reference intervals but on diagnostic values defined as categories in classification system shown in Table 2. Implementation of equations listed in Table 6, in laboratory information system is necessary for calculating eGFR using CKD-EPI equation. Recommended equations relate to white race. For calculating eGFR in black race, obtained result must be multiplied by 1.159. When reporting eGFR results, they should be rounded to a nearest whole number using the recommended units mL/min/1.73 m2. eGFR values should be reported with requests for serum creatinine concentration in adults (5).
Glomerular filtration rate physiologically decreases with ageing by approximately 1 mL/min/year of age (52, 53). Although an eGFR values < 60 mL/min/1.73 m2 are very common in older people (5), it is predictive for increased risk of adverse clinical outcomes and age related diagnostic values for eGFR are not recommended in adults.
Based on the biological and analytical variation of serum creatinine, the reference change value (RCV) for eGFR is about 14%.
For estimation of GFR in pediatric population we recommend Schwartz equation with obligatory use of enzymatic assay for the measurement of serum creatinine concentration (54, 55). The equation is applicable for children from 1 to 18 years old.
Routine calculation of eGFR is not recommended in children and youth (5). Every eGFR result calculated by Schwartz equation above than 75 mL/min/1.73 m2 should not be reported as a whole number but as „> 75 mL/min/1.73 m2“.
In children younger than 2 years of age with CKD, the GFR categories as per the adult in Table 2 do not apply; these children should be categorized as having normal, moderately reduced, or severely reduced age-adjusted GFR. No currently agreed upon set of international normative values or categories exist for GFR in children under the age of 1-2 years. However, the international pediatric nephrology community has embraced the adult CKD staging system as per the 2002 KDOQI guidelines in children over the age of 2 years (1).
Laboratories should implement the 2009 CKD-EPI equation for estimation of GFR.
eGFR results should be reported with serum creatinine results in adults.
eGFR results should be rounded to a nearest whole number using the recommended units mL/min/1.73 m2.
Age related diagnostic values for eGFR are not recommended in adults.
Low eGFR values should be confirmed with a repeat sample taken after avoidance of meat at least 12 hours. Additionally, spurious causes of low eGFR should be considered and should prompt a check for proteinuria.
RCV for eGFR is ~14%.
The recommended equation for children under 18 years is the Schwartz equation.
Routine calculation of eGFR is not recommended in children and youth.
Every eGFR result calculated by Schwartz equation above than 75 mL/min/1.73 m2 should be reported as „> 75 mL/min/1.73 m2”.
The GFR categories (listed in the Table 2) do not apply in children under 2 years of age.
Albumin intra- and inter-individual biological variation are important factors for selecting appropriate urine sample, for the interpretation of the confirmation results and for assessing clinically significant difference in albumin concentration. ACR in the first morning urine has a significantly lower intra-individual variation, compared to the albumin concentration in 24-hour urine. This represents an important fact considering the pitfalls in collecting 24-hour urine samples (56). Table 7 presents the factors affecting urinary ACR (1, 57).
|Factor||Examples of effect||Actions|
|Intraindividual variability||Genetic variability||
Laboratory professionals and clinicians should be aware of listed limitations.
For a better flow of information please consult the Appendix 2.
|Non-renal causes of variability in creatinine excretion||
Age (lower in children and elderly)
Race (lower in Caucasians than black people)
Muscle mass (lower in people with amputations, paraplegia, muscular dystrophy)
Gender (lower in women)
|Changes in creatinine excretion||AKI|
|Transient elevation in albuminuria||
Menstrual blood contamination
Symptomatic urinary tract infections
Other conditions increasing vascular permeability (e.g. septicemia, significant hypertension, fever)
For obtaining an adequate sample laboratory professionals should implement standards of good laboratory practice issued by CCMB, available at: http://www.hkmb.hr/povjerenstva/strucna-pitanja.html
Patients should be thoroughly explained about possible in vivo influence factors.
|Transient elevation in proteinuria||
Vaginal and urethral secretions contamination
Very high protein intake
Diluted urine specimens can give false negative protein results
|Preanalytical storage conditions||Degradation of albumin before analysis||
Albumin is stable in urine samples without preservatives at least one week when stored at 2-8 °C.
For an extended period it is recommended to freeze the sample at - 80 °C, without centrifugation or filtration.
After thawing of the sample, possible precipitates can be easily removed by dissolving the sample at 37 °C. Blurry urine samples should be centrifuged.
|Degradation of total protein before analysis||The proteins are susceptible to bacterial degradation at room temperature. Analysis should be performed as quickly as possible. Samples may be stored for up to 1 week at + 4 °C, for longer storage frozen at -20 °C or at - 80 °C. Samples should be dissolved at 37 °C to prevent degradation of proteins and after homogenizing, samples should be centrifuged prior to analysis|
ACR - albumin-to-creatinine ratio. PCR - protein-to-creatinine ratio. AKI - acute kidney injury. CCMB - Croatian Chamber of Medical Biochemists.
(Reproduced and adapted with permission from KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int, Suppl 2013;3:1-150.)
The majority of the variations listed are non-controllable, however both laboratory professionals and clinicians should be aware of those limitations. Controllable variations include obtaining an adequate urine sample. The patient should be adequately prepared and told why a urine specimen requires to be examined. Instructions on how it should be collected should be given, ideally both orally and in written form, following the national recommendations issued by CCMB about standards of good laboratory practice in obtaining adequate urine samples (58). Biological (in vivo) factors, changing the true concentration of a measured component, cause problems in the interpretation of laboratory results, although the measurement process itself is correct. They are called influence factors and patients should be adequately explained about possible interferences (59).
Albumin is stable in urine samples without preservatives at least one week when stored at 2-8 °C. For an extended period it is recommended to freeze the sample at –80 °C, without centrifugation or filtration. After sample thawing, possible precipitates can be easily removed by dissolving the sample at 37 °C. Blurry urine samples should be centrifuged (60).
Recommended methods for the measurement of urine albumin are immunochemistry assays, specific and precise at low albumin concentrations, that produce quantitative results in clinically relevant range. Albumin is mainly measured using turbidimetric assays. Currently there is no reference measurement procedure or standardized reference material recommended by the Joint Committee on Traceability in Laboratory Medicine (JCTLM). At the moment the LC-IDMS method developed at the Mayo Clinic Renal Reference Laboratory is under validation at the National Institute for Standards and technology (NIST) before being submitted to the JCTLM for listing (61). Most methods are standardized against the Standard Reference Material 470 (SRM 470) distributed by the Institute for Reference Materials and Measurements (IRMM) of the European Commission (1), however the NIST SRM 2925 containing pure albumin intended for calibration of LC-IDMS is now available. The commutability assessment of the NIST SRM 3666 containing albumin in frozen human urine intended for calibration of routine measurements procedures is at the moment under investigation (61). Since the results are expressed in proportion to the concentration of creatinine, urine creatinine should be measured in the same urine sample.
Desirable and optimal specifications for imprecision, bias and total error according to biological variation database (14) are shown in Table 4.
Samples with very high albumin concentration may give falsely low or normal results due to the prozone effect. In this case it is necessary to repeat the analysis after dilution of the sample.
The main causes of variation in urine albumin measurement are outside the analytical process, in preanalytical (as described in the previous subheading) and postanalytical phases (different units, different cut-off values, different ways of reporting the results). Other causes of variation are different forms of albumin in urine, which are significantly different from each other even between healthy individuals. Urine albumin is exposed to modifying factors such as wide range of pH and ionic strength, high concentrations of urea, glucose and ascorbate, and cleavage by peptidases (62).
The presence of albumin in urine should be expressed as categories of classification system shown in Table 2. The term microalbuminuria is no longer recommended.
The results should be reported as ACR expressed as mg/mmol. If the presence of albumin in urine is measured as AER results should be reported using the units mg/24 hours with reference interval < 30 mg/24hours, independently of sex and age.
There is no set standard encompassing all children with respect to the normal range of urinary protein (or albumin) excretion. Values vary across age, sex, puberty, the presence of obesity (high BMI) and may be modified by exercise, fever and posture (1).
In children with CKD any expression of abnormal urinary protein excretion may utilize proteinuria in place of albuminuria. Children older than 24 months of age are expected to achieve normal (adult) protein values (1).
Measure albumin preferably in a morning urine specimen.
Measure urine creatinine in the same urine sample.
Express the results as albumin-to-creatinine ratio (ACR) in recommended units (mg/mmol).
A positive finding of albuminuria in a random sample of urine needs to be confirmed in the next morning void urine.
If a more accurate estimate of albuminuria is required, it is recommended to measure albumin excretion rate (AER), with reference interval < 30 mg/24hours, independently of sex and age.
In children with CKD proteinuria should be preferred over albuminuria, especially in children < 2 years of age.
Adult values for AER and ACR apply for children older than 24 months of age.
Filtered serum proteins, proteins derived from the kidney and urinary tract make normal urine protein content (63). Their appearance is influenced by renal, pre- and postrenal conditions (64). Urine as a body fluid for clinical analysis is relatively stable, probably due to the fact that it is “stored” for hours in the bladder; hence, proteolytic degradation by endogenous proteases may be essentially complete by the time of voiding (65).
Total protein in urine may be increased after heavy exercise, dehydration, very high protein intake and emotional stress (66). Vaginal and urethral secretions can produce false positive, and diluted urine specimens can give false negative protein results (67). Because urine albumin is predominant protein in most proteinuric kidney diseases, all factors affecting urinary ACR also affect PCR (Table 7).
Proteins are susceptible to bacterial degradation at room temperature. Analysis should be performed as quickly as possible. Samples may be stored for up to 1 week at + 4 °C, for longer storage frozen at –20 °C or at –80 °C. Samples should be dissolved at 37 °C to prevent degradation of proteins and after homogenizing, samples should be centrifuged prior to analysis (68).
There is no recommended method for measuring of total protein in the urine. The majority of laboratories use turbidimetric or colorimetric assays. These methods do not have the same analytical specificity and sensitivity for all proteins. Most methods reacts more strongly with albumin than with globulins and other non-albumin proteins.
There is no reference method and no standardized reference material for urine protein recommended by JCTLM. Different methods and calibrators lead to significant between-laboratory variation. It is difficult to define a standardized reference material since a variable mixture of different proteins is measured (1).
Desirable and optimal specifications for imprecision, bias and total error according to biological variation database (14) are shown in Table 4.
Results of total urine protein measurement should be reported as PCR using the units mg/mmol (Table 8).
Normal to mild proteinuria
|< 15.0 mg/mmol|
|15.0 - 50.0 mg/mmol|
|> 50.0 mg/mmol|
Measurement of PCR to total protein concentration, in initial assessment of proteinuria, is to overcome variation in urine concentration and dilution (63).
Neonates and young infants/children are both expected and allowed to have higher urinary losses of both glomerular and tubular proteinuria due to lack of maturation in the proximal tubular reabsorption of proteins. In children the quantification of total protein, as compared to the albumin only fraction, may be preferred method (1).
The normal ranges for albuminuria and proteinuria in children are shown in Table 9.
Measure total protein preferably in a morning urine specimen.
Measure urine creatinine in the same urine sample.
Express the results as protein-to-creatinine ratio (PCR) in recommended units (mg/mmol).
A positive finding of proteinuria in a random sample of urine should be confirmed in the next morning void urine.
In adults, for a measure of protein excretion rate (PER) apply reference interval < 150 mg/24hours, independently of sex and age.
In children, the quantification of total protein, as compared to the albumin only fraction, may be preferred method.
There are many issues that need to be resolved in the laboratory diagnostics of CKD in Croatia (8). Although there were many potential biomarkers suggested for the early diagnosis of CKD (69, 70), considering the issues that were raised via the conducted survey (8), we need to approach the Croatian medical biochemistry laboratories at the very basic level.
The principal clinical purpose of assessing a patient’s renal function is to anticipate complications, enabling better screening and treatment decisions. Determining with great accuracy a certain physiologic parameter – actual GFR – is a less important goal (71) and inexpensive, easy and accurate measurement of serum creatinine could lead to reduction in the global burden of CKD (3). In connection to this, the very first goal is to introduce standardized assays for creatinine measurement and eGFR reporting in all medical biochemistry laboratories. The second goal is to harmonize the choice of the sample for ACR/PCR measurement and the reporting units, consequently.
The future perspectives include education in implementing the recommendations and conducting tho follow-up survey to observe the completeness and identifying „weak spots“ of the recommendations implementation process. The obtained data will be a starting point for the second edition of the recommendations.
In conclusion, reporting the results of laboratory tests for the diagnosis of CKD should be aligned with the adopted general recommendations with the applicable reference intervals, diagnostic value, and the source is acknowledged criteria. An example of the recommended reporting in laboratory diagnostics of CKD is shown in Table 10.